

Alessandra Tucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8642418/publications.pdf>

Version: 2024-02-01

117
papers

5,466
citations

87723

38
h-index

85405

71
g-index

117
all docs

117
docs citations

117
times ranked

5629
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	2.2	442
2	Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood</i> , 2007, 110, 2316-2323.	0.6	293
3	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	2.2	258
4	A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. <i>Cancer</i> , 2009, 115, 4547-4553.	2.0	255
5	Prospective, multicenter randomized GITMO/III trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
6	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
7	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006, 107, 4643-4649.	0.6	217
8	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
9	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet</i> , 2019, 394, 2271-2281.	6.3	155
10	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
11	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). <i>Leukemia and Lymphoma</i> , 2015, 56, 921-926.	0.6	139
12	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
13	Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 2654-2661.	0.8	130
14	Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. <i>Leukemia and Lymphoma</i> , 2006, 47, 1013-1017.	0.6	124
15	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
16	A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. <i>Blood</i> , 1996, 87, 1416-1422.	0.6	103
17	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2017, 18, 1076-1088.	5.1	100
18	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	3.2	94

#	ARTICLE	IF	CITATIONS
19	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	1.7	91
20	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
21	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
22	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
23	Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. <i>Cancer</i> , 2020, 126, 5069-5076.	2.0	69
24	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
25	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014, 99, 1387-1394.	1.7	63
26	Prevalence of <i>Borrelia burgdorferi</i> Infection in a Series of 98 Primary Cutaneous Lymphomas. <i>Oncologist</i> , 2011, 16, 1582-1588.	1.9	61
27	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012, 97, 416-422.	1.7	61
28	Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3998-4004.	3.2	60
29	Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 87-96.	3.3	59
30	Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 3351-3359.	0.8	54
31	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013, 98, 1732-1738.	1.7	54
32	Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 77-81.	0.6	50
33	Are cord blood B cells functionally mature?. <i>Clinical and Experimental Immunology</i> , 1991, 84, 389-94.	1.1	49
34	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
35	Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2019, 33, 449-458.	1.2	48
36	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , 2010, 151, 221-231.	1.2	47

#	ARTICLE	IF	CITATIONS
37	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	3.3	47
38	The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. <i>Cancer</i> , 2019, 125, 1674-1682.	2.0	45
39	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. <i>Blood</i> , 1997, 90, 1309-1314.	0.6	43
40	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007, 110, 121-128.	2.0	41
41	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. <i>Annals of Oncology</i> , 2008, 19, 1331-1335.	0.6	40
42	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	0.8	34
43	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
44	Self tolerance to human A and B histo-blood group antigens exists at the B cell level and cannot be broken by potent polyclonal B cell activation in vitro. <i>European Journal of Immunology</i> , 1992, 22, 2713-2717.	1.6	33
45	Prognostic role of baseline ¹⁸ F-FDG PET/CT parameters in MALT lymphoma. <i>Hematological Oncology</i> , 2019, 37, 39-46.	0.8	33
46	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
47	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. <i>Blood Cancer Journal</i> , 2021, 11, 151.	2.8	32
48	slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <i>Cancer Research</i> , 2018, 78, 3544-3559.	0.4	31
49	Prognostic role of baseline ¹⁸ F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. <i>Annals of Hematology</i> , 2020, 99, 1321-1330.	0.8	30
50	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	0.8	29
51	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.	3.3	27
52	Effects of eleven cytokines and of IL-1 and tumor necrosis factor inhibitors in a human B cell assay. <i>Journal of Immunology</i> , 1992, 148, 2778-84.	0.4	27
53	Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. <i>European Journal of Immunology</i> , 1993, 23, 1469-1474.	1.6	24
54	Preneoplastic somatic mutations including MYD88 ^{L265P} in lymphoplasmacytic lymphoma. <i>Science Advances</i> , 2022, 8, eabl4644.	4.7	21

#	ARTICLE	IF	CITATIONS
55	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	1.2	20
56	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012, 23, 729-735.	0.6	19
57	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. <i>Hematological Oncology</i> , 2019, 37, 153-154.	0.8	19
58	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens. <i>Haematologica</i> , 2020, 105, 1369-1378.	1.7	19
59	Prognostic impact of <i>TP53</i> mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FOLL12 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.	1.2	19
60	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 12-25.	0.6	18
61	Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1042-1055.	2.9	18
62	Transformation of a MGUS to Overt Multiple Myeloma: The Possible Role of a Pituitary Macroadenoma Secreting High Levels of Insulin-like Growth Factor 1 (IGF-1). <i>Leukemia and Lymphoma</i> , 2003, 44, 543-545.	0.6	16
63	Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. <i>American Journal of Hematology</i> , 2020, 95, 759-765.	2.0	16
64	Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of ¹⁸ F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation. <i>British Journal of Radiology</i> , 2021, 94, 20200672.	1.0	15
65	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. <i>Haematologica</i> , 2022, 107, 1153-1162.	1.7	15
66	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	0.5	14
67	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019, 104, 2241-2248.	1.7	13
68	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	1.2	12
69	Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1467-1470.	0.6	12
70	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018, 59, 2904-2910.	0.6	11
71	Diagnostic and Clinical Impact of Staging ¹⁸ F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e457-e464.	0.2	11
72	The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020, 99, 277-282.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). <i>Blood</i> , 2007, 110, 1278-1278.	0.6	10
74	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	2.0	9
75	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 880-887.	0.6	9
76	Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET/CT in Elderly Mantle Cell Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1210.	1.0	9
77	Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study. <i>International Journal of Surgery</i> , 2017, 41, 143-149.	1.1	8
78	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8
79	Prognostic role of ¹⁸ F-MTV and ¹⁸ F-TLG in Burkitt lymphoma. <i>Annals of Nuclear Medicine</i> , 2019, 33, 280-287.	1.2	8
80	Serum levels of polychlorinated biphenyls and risk of non-Hodgkin lymphoma: A hospital-based case-control study. <i>Chemosphere</i> , 2019, 235, 969-975.	4.2	7
81	Prognostic Role of "Radiological" Sarcopenia in Lymphoma: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e340-e349.	0.2	7
82	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
83	Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 3209-3216.	0.6	6
84	Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer. <i>Acta Oncologica</i> , 2008, 47, 464-466.	0.8	5
85	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. <i>Blood</i> , 2010, 116, 432-432.	0.6	5
86	Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2011, 152, 113-116.	1.2	4
87	Follicular lymphomas in vulnerable/older patients. <i>Current Opinion in Oncology</i> , 2019, 31, 380-385.	1.1	4
88	A brief rituximab, bendamustine, mitoxantrone (R ² BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
89	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). <i>Blood</i> , 2011, 118, 777-777.	0.6	4
90	Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial. <i>Blood</i> , 2013, 122, 551-551.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Historical perspectives of collagen diseases. <i>Clinics in Dermatology</i> , 1992, 10, 393-397.	0.8	3
92	The "Elderly Project" by The Fil (Fondazione Italiana Linfomi): A project aimed at the prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2014, 5, S11-S12.	0.5	3
93	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.	2.0	3
94	Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. <i>Tumori</i> , 2018, 104, 394-400.	0.6	3
95	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010, 116, 966-966.	0.6	3
96	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 850-850.	0.6	3
97	Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. <i>Annals of Oncology</i> , 2008, 19, 951-957.	0.6	2
98	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 2677-2680.	0.6	2
99	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013, 122, 3047-3047.	0.6	2
100	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). <i>Blood</i> , 2013, 122, 3049-3049.	0.6	2
101	Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2014, 124, 1755-1755.	0.6	2
102	The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015, 126, 2735-2735.	0.6	2
103	Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.. <i>Blood</i> , 2005, 106, 676-676.	0.6	2
104	In Vitro Function of Peripheral Blood and Peritoneal B Lymphocytes from Capd Patientsa. <i>Peritoneal Dialysis International</i> , 1994, 14, 84-86.	1.1	1
105	Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized III Trial. <i>Blood</i> , 2008, 112, 834-834.	0.6	1
106	The Role Of Qualitative FDG-PET Assessment Using The 5 Point Deauville Scale For Postinduction Response Assessment In Patients With Follicular Lymphoma. A Study From The Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2013, 122, 4295-4295.	0.6	1
107	Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial. <i>Blood</i> , 2015, 126, 1547-1547.	0.6	1
108	Dissection of B cell immune responses in autoimmune diseases by the methodology of human MoAbs production. <i>Human Immunology</i> , 1988, 23, 96-97.	1.2	0

#	ARTICLE	IF	CITATIONS
109	Normal and atopic IgE responses. <i>Seminars in Immunopathology</i> , 1993, 15, 29-36.	4.0	0
110	Palliative chemotherapy is not the best choice. <i>Journal of Geriatric Oncology</i> , 2012, 3, S18.	0.5	0
111	Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2014, 20, S26-S27.	0.7	0
112	The "Elderly Project" by the Fondazione Italiana Linfomi (FIL): a prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2015, 26, vi134.	0.6	0
113	Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.. <i>Blood</i> , 2004, 104, 1321-1321.	0.6	0
114	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 478-478.	0.6	0
115	Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (ILL).. <i>Blood</i> , 2009, 114, 2316-2316.	0.6	0
116	Association of Hodgkin Lymphoma and Non-Hodgkin Lymphoma In the Same Patient. Clinicopathologic Characteristics and Outcome In a Series of 20 Cases. <i>Blood</i> , 2010, 116, 3886-3886.	0.6	0
117	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 3653-3653.	0.6	0